Clinical Trial Search

Primary: Deterioration-free Survival Rate of the QOL Global Health Status at 3, 6 and 12 Months (Mos) — 89; 73; 74; 59 percentage of participants

Primary: Prolonged Abstinence Rates — 36.00; 30.43 Percentage of participants

Primary: Linkage to HIV Care (Indicated by a HIV-related Laboratory Blood Test Within 8 Months) — 88; 74; 93; 90 Participants

Primary: Number of Participants With at Least 1 Adverse Event (AE) of Grade 3 or 4 Based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)…

Primary: 12 Month Kaplan-Meier Estimate of Major CIED Infection Rate — 0.7; 1.2 Percentage of subjects — p=0.0406

Primary: Frequencies At Which Changes in Alpha, Theta, and Slow-Delta Wave Power Were Observed From Baseline During Sevoflurane-induced General Anesthesia — 10; 5; 1 Hz

Primary: Timed Get Up and Go (TGUG) — 24.8; 21.6 seconds

Primary: Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) After the Second Infusion of the First Dose — 149398; 172463; 158529 h*µg/mL

Primary: Amplitude Asymmetry of Pupil Constriction — 0.8; 0.29; 0.5; 0.16 millimeters

Primary: Patient Reported Outcome Measure (Patient Percention of Bladder Condition Question) — 4; 3 units on a scale

Primary: Contraception Use Self-efficacy Scale Score (Aim 1b) — 23.2; 22.45; 25.22; 23.04 Scores on a scale — p=0.011

Primary: Ureteral Jet Visibility — 22; 35; 27; 41 Participants

Primary: Effective Phaco Time (EPT) — 1.48; 2.3 EPT

Primary: Number of Participants With Same Results With GE VScan and Full Transthoracic Echocardiogram — 66 Participants — p=0.0005

Primary: Percentage of Participants Who Had One or More Adverse Drug Reactions — 2.30 Percentage of Participants